These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37723308)

  • 1. Effect of denosumab on bone mineral density in a postmenopausal osteoporotic woman with prolonged chronic mild hyponatremia.
    Fujishima R; Ushimaru S; Sumi H; Aso M; Akaike T; Shiizaki K; Tominaga N
    Osteoporos Int; 2023 Dec; 34(12):2139-2140. PubMed ID: 37723308
    [No Abstract]   [Full Text] [Related]  

  • 2. [Multiple vertebral fractures after rebound effect of denosumab in postmenopausal woman].
    Ricart Torres E
    Aten Primaria; 2024 Feb; 56(2):102810. PubMed ID: 37976777
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
    Ha J; Kim J; Jeong C; Lim Y; Kim MK; Kwon HS; Song KH; Kang MI; Baek KH
    Osteoporos Int; 2022 Jul; 33(7):1591-1599. PubMed ID: 35376989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable loss of bone mineral density in 6 months after denosumab discontinuation: a case report.
    Maezumi Y; Kamimura M; Nakamura Y; Takahashi J
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):218-221. PubMed ID: 33087002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
    Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
    Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab versus Bisphosphonates for Reducing Fractures in Postmenopausal Women with Osteoporosis: A Meta-Analysis.
    Thal KA; Nudy M; Moser EM; Foy AJ
    J Am Board Fam Med; 2023 Feb; 36(1):175-185. PubMed ID: 36653115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dilemma of denosumab therapy: rebound fractures with denosumab cessation or dose delay.
    Herath M; Wong P; Milat F
    Intern Med J; 2021 Feb; 51(2):297-298. PubMed ID: 33631850
    [No Abstract]   [Full Text] [Related]  

  • 9. Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis".
    Torrente-Segarra V; Roig-Vilaseca D
    Rheumatol Int; 2018 Jun; 38(6):1161-1162. PubMed ID: 29546636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
    Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis.
    Zeytinoglu M; Naaman SC; Dickens LT
    Endocrinol Metab Clin North Am; 2021 Jun; 50(2):205-222. PubMed ID: 34023039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia.
    Růžičková O; Killinger Z; Kasalický P; Hamilton L; Tyl R; Tomková S; Kalouche-Khalil L
    Adv Ther; 2018 Oct; 35(10):1713-1728. PubMed ID: 30191465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
    Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
    Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
    [No Abstract]   [Full Text] [Related]  

  • 17. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it necessary to modify the clinical trials about osteoporosis? The serious problem of denosumab.
    Sosa Henríquez M; Gómez de Tejada Romero MJ; Torregrosa Suau O
    Med Clin (Barc); 2020 Aug; 155(4):184-185. PubMed ID: 31445748
    [No Abstract]   [Full Text] [Related]  

  • 19. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.
    Miyoshi A; Kameda H; Nagai S; Nakamura A; Miya A; Takase T; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1293-1300. PubMed ID: 33141482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
    Jamshidi A; Vojdanian M; Soroush M; Akbarian M; Aghaei M; Hajiabbasi A; Mirfeizi Z; Khabbazi A; Alishiri G; Haghighi A; Salimzadeh A; Karimzadeh H; Shirani F; Fard MRH; Nazarinia M; Soroosh S; Anjidani N; Gharibdoost F
    Arthritis Res Ther; 2022 Jun; 24(1):161. PubMed ID: 35773713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.